| 1 | developing innovative therapies for | | | | | | | 4 | 2.07% |
| 2 | therapies for neuropsychiatric disorders | | | | | | | 3 | 1.55% |
| 3 | pharmaceuticals inc a privatelyheld | | | | | | | 3 | 1.55% |
| 4 | inc a privatelyheld biopharmaceutical | | | | | | | 3 | 1.55% |
| 5 | innovative therapies for neuropsychiatric | | | | | | | 3 | 1.55% |
| 6 | a privatelyheld biopharmaceutical company | | | | | | | 2 | 1.04% |
| 7 | privatelyheld biopharmaceutical company is | | | | | | | 2 | 1.04% |
| 8 | disorders learn more home | | | | | | | 2 | 1.04% |
| 9 | learn more home technology | | | | | | | 1 | 0.52% |
| 10 | leadership and ideas home | | | | | | | 1 | 0.52% |
| 11 | and ideas home company | | | | | | | 1 | 0.52% |
| 12 | company developing innovative therapies | | | | | | | 1 | 0.52% |
| 13 | homehomehomehome about promentis management | | | | | | | 1 | 0.52% |
| 14 | more home technology novel | | | | | | | 1 | 0.52% |
| 15 | home technology novel oral | | | | | | | 1 | 0.52% |
| 16 | world class leadership and | | | | | | | 1 | 0.52% |
| 17 | technology novel oral compounds | | | | | | | 1 | 0.52% |
| 18 | novel oral compounds engaging | | | | | | | 1 | 0.52% |
| 19 | class leadership and ideas | | | | | | | 1 | 0.52% |
| 20 | world class leadership | | | | | | | 1 | 0.52% |
| 21 | compounds engaging system xca | | | | | | | 1 | 0.52% |
| 22 | of trichotillomania as well | | | | | | | 1 | 0.52% |
| 23 | function have been proposed | | | | | | | 1 | 0.52% |
| 24 | have been proposed to | | | | | | | 1 | 0.52% |
| 25 | been proposed to contribute | | | | | | | 1 | 0.52% |
| 26 | proposed to contribute to | | | | | | | 1 | 0.52% |
| 27 | to contribute to the | | | | | | | 1 | 0.52% |
| 28 | underlying pathology of trichotillomania | | | | | | | 1 | 0.52% |
| 29 | pathology of trichotillomania as | | | | | | | 1 | 0.52% |
| 30 | trichotillomania as well as | | | | | | | 1 | 0.52% |
| 31 | background world class | | | | | | | 1 | 0.52% |
| 32 | about promentis management board | | | | | | | 1 | 0.52% |
| 33 | obsessivecompulsive and addictive disorders | | | | | | | 1 | 0.52% |
| 34 | and addictive disorders and | | | | | | | 1 | 0.52% |
| 35 | addictive disorders and other | | | | | | | 1 | 0.52% |
| 36 | disorders and other cns | | | | | | | 1 | 0.52% |
| 37 | and other cns conditions | | | | | | | 1 | 0.52% |
| 38 | parallax background world | | | | | | | 1 | 0.52% |
| 39 | oral compounds engaging system | | | | | | | 1 | 0.52% |
| 40 | target for diverse psychiatric | | | | | | | 1 | 0.52% |